FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365514091> ?p ?o ?g. }

• W4365514091 endingPage "CT030" @default.
• W4365514091 startingPage "CT030" @default.
• W4365514091 abstract "Abstract Background: IBI351 (GFH925) is an irreversibly covalent inhibitor of KRASG12C. Data from prior data cutoffs (primary: Feb, 2022; initial update: July, 2022) showed that IBI351 (GFH925) was well-tolerated and demonstrated promising efficacy in patients (pts) with advanced solid tumors harboring KRAS p.G12C mutation. Here, we update results of this phase I study evaluating IBI351 (GFH925) in pts with advanced solid tumors again. Methods: Pts with locally advanced, recurrent or metastatic solid tumors with KRASG12C mutation for whom standard therapy had failed were enrolled. Phase I dose escalation had an accelerated titration design for dose level 250mg once daily (QD) and a Bayesian optimal interval (BOIN) design with 450-900mg QD and 450-750mg twice daily (BID). The primary endpoints were safety and tolerability. The secondary endpoints were pharmacokinetics (PK), anti-tumor activity of IBI351 (GFH925) monotherapy per RECIST v1.1, and overall survival. Results: As of November 30th, 2022, 74 pts (1 at 250mg QD, 3 at 450mg QD, 9 at 700mg QD, 5 at 900mg QD, 21 at 450mg BID, 31 at 600mg BID and 4 at 750mg BID; 62 men, 12 women; median age: 64 yrs, range: 42-76 yrs) were enrolled, among whom 67 pts had non-small cell lung cancer (NSCLC). Among 67 NSCLC pts, 44.8% pts received ≥2 prior lines of treatment (tx), 38.8% pts had brain metastases; adenocarcinoma was the most common histology (n=66, 98.5%). All 74 pts were included for safety analysis. No dose-limiting toxicity (DLT) were observed in any dose cohorts. The overall safety profile was consistent with the latest previous report, with no new safety signals identified. As of December 15th, 2022, among 67 response-evaluable NSCLC pts across all dose levels, the ORR (by investigator assessment) was 58.2% (95% CI, 45.5-70.2), and the confirmed ORR was 44.8% (95% CI, 32.6-57.4); the disease control rate (DCR) was 92.5% (95% CI, 83.4-97.5). At the 600mg BID dose level (RP2D), the ORR was 63.3% (95% CI, 43.9-80.1), and the confirmed ORR was 50.0% (95% CI, 31.3-68.7), the DCR was 96.7% (95% CI, 82.8-99.9). With a median progression-free survival (PFS) follow-up of 5.5 months (95% CI, 5.3-6.8) for NSCLC pts at the 600mg BID dose level, 21 (70%) pts were continuing treatments, and the median duration of response (DoR) and PFS were not reached. Thirteen out of 15 confirmed responders were still in response. Conclusion: IBI351 (GFH925) was well-tolerated across all doses explored in patients with advanced solid tumors harboring KRAS p.G12C mutation. The data also demonstrated promising efficacy and durable response of IBI351 (GFH925) in previously treated advanced NSCLC. Clinical trial information: NCT05005234. Citation Format: Qing Zhou, Nong Yang, Jun Zhao, Mingfang Zhao, Yan Yu, Ying Yuan, Huijuan Wang, Xingya Li, Xiaorong Dong, Longhua Sun, Tongmei Zhang, Dingzhi Huang, Qian Chu, Jingjing Huang, Sujie Zhang, Mengna Huang, Yuping Shen, Yi-Long Wu. Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT030." @default.
• W4365514091 created "2023-04-15" @default.
• W4365514091 creator A5000243199 @default.
• W4365514091 creator A5008115520 @default.
• W4365514091 creator A5008937427 @default.
• W4365514091 creator A5010405626 @default.
• W4365514091 creator A5011925285 @default.
• W4365514091 creator A5012037589 @default.
• W4365514091 creator A5022202296 @default.
• W4365514091 creator A5029683591 @default.
• W4365514091 creator A5029786366 @default.
• W4365514091 creator A5036519850 @default.
• W4365514091 creator A5053655037 @default.
• W4365514091 creator A5064745999 @default.
• W4365514091 creator A5076756498 @default.
• W4365514091 creator A5077703494 @default.
• W4365514091 creator A5083357029 @default.
• W4365514091 creator A5086109274 @default.
• W4365514091 creator A5086532638 @default.
• W4365514091 creator A5087828355 @default.
• W4365514091 date "2023-04-14" @default.
• W4365514091 modified "2023-09-28" @default.
• W4365514091 title "Abstract CT030: Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study" @default.
• W4365514091 doi "https://doi.org/10.1158/1538-7445.am2023-ct030" @default.
• W4365514091 hasPublicationYear "2023" @default.
• W4365514091 type Work @default.
• W4365514091 citedByCount "0" @default.
• W4365514091 crossrefType "journal-article" @default.
• W4365514091 hasAuthorship W4365514091A5000243199 @default.
• W4365514091 hasAuthorship W4365514091A5008115520 @default.
• W4365514091 hasAuthorship W4365514091A5008937427 @default.
• W4365514091 hasAuthorship W4365514091A5010405626 @default.
• W4365514091 hasAuthorship W4365514091A5011925285 @default.
• W4365514091 hasAuthorship W4365514091A5012037589 @default.
• W4365514091 hasAuthorship W4365514091A5022202296 @default.
• W4365514091 hasAuthorship W4365514091A5029683591 @default.
• W4365514091 hasAuthorship W4365514091A5029786366 @default.
• W4365514091 hasAuthorship W4365514091A5036519850 @default.
• W4365514091 hasAuthorship W4365514091A5053655037 @default.
• W4365514091 hasAuthorship W4365514091A5064745999 @default.
• W4365514091 hasAuthorship W4365514091A5076756498 @default.
• W4365514091 hasAuthorship W4365514091A5077703494 @default.
• W4365514091 hasAuthorship W4365514091A5083357029 @default.
• W4365514091 hasAuthorship W4365514091A5086109274 @default.
• W4365514091 hasAuthorship W4365514091A5086532638 @default.
• W4365514091 hasAuthorship W4365514091A5087828355 @default.
• W4365514091 hasConcept C121608353 @default.
• W4365514091 hasConcept C126322002 @default.
• W4365514091 hasConcept C126894567 @default.
• W4365514091 hasConcept C143998085 @default.
• W4365514091 hasConcept C197934379 @default.
• W4365514091 hasConcept C2778375690 @default.
• W4365514091 hasConcept C2779984678 @default.
• W4365514091 hasConcept C2781187634 @default.
• W4365514091 hasConcept C29730261 @default.
• W4365514091 hasConcept C31760486 @default.
• W4365514091 hasConcept C526805850 @default.
• W4365514091 hasConcept C71924100 @default.
• W4365514091 hasConcept C90924648 @default.
• W4365514091 hasConceptScore W4365514091C121608353 @default.
• W4365514091 hasConceptScore W4365514091C126322002 @default.
• W4365514091 hasConceptScore W4365514091C126894567 @default.
• W4365514091 hasConceptScore W4365514091C143998085 @default.
• W4365514091 hasConceptScore W4365514091C197934379 @default.
• W4365514091 hasConceptScore W4365514091C2778375690 @default.
• W4365514091 hasConceptScore W4365514091C2779984678 @default.
• W4365514091 hasConceptScore W4365514091C2781187634 @default.
• W4365514091 hasConceptScore W4365514091C29730261 @default.
• W4365514091 hasConceptScore W4365514091C31760486 @default.
• W4365514091 hasConceptScore W4365514091C526805850 @default.
• W4365514091 hasConceptScore W4365514091C71924100 @default.
• W4365514091 hasConceptScore W4365514091C90924648 @default.
• W4365514091 hasIssue "8_Supplement" @default.
• W4365514091 hasLocation W43655140911 @default.
• W4365514091 hasOpenAccess W4365514091 @default.
• W4365514091 hasPrimaryLocation W43655140911 @default.
• W4365514091 hasRelatedWork W1833952634 @default.
• W4365514091 hasRelatedWork W2148536479 @default.
• W4365514091 hasRelatedWork W2759045790 @default.
• W4365514091 hasRelatedWork W2793494425 @default.
• W4365514091 hasRelatedWork W2910623846 @default.
• W4365514091 hasRelatedWork W2912967573 @default.
• W4365514091 hasRelatedWork W2994319618 @default.
• W4365514091 hasRelatedWork W3167619469 @default.
• W4365514091 hasRelatedWork W3197516152 @default.
• W4365514091 hasRelatedWork W4308381391 @default.
• W4365514091 hasVolume "83" @default.
• W4365514091 isParatext "false" @default.
• W4365514091 isRetracted "false" @default.
• W4365514091 workType "article" @default.